KZ
Kezar Life Sciences, Inc.
KZR · NASDAQ
$7.29 +0.00% (+$0.00)
Market Cap $53.9M
P/E Ratio -
Div. Yield -
ROE 62.53%
Bulios Fair Price
$7.11
2.5% downside
Current Price
$7.29
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KZR is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/B 0.65x
EV/EBITDA N/A
P/S N/A
Growth
80 /100
Growing Book val. growth 9.99%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 62.53%
ROA 63.14%
Asset turnover 0.00x
Debt
80 /100
Low Current ratio 7.06x
Int. coverage -58.45x
Net debt/EBITDA 0.49x
Stability
56 /100
Moderate EPS volatility 21.31%
Profitable years 0
Beta 0.41x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KZR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Christopher J. Kirk
Employees
55
Headquarters
South San Francisco